News

Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?

  • Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
    04/03/2024

Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?

  • Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
    03/18/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Aadi Bioscience, Inc. (AADI) can sell. Click on Rating Page for detail.

The price of Aadi Bioscience, Inc. (AADI) is 1.75 and it was updated on 2024-04-28 07:00:40.

Currently Aadi Bioscience, Inc. (AADI) is in undervalued.

News
    
News

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates

  • Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago.
    Wed, Mar. 13, 2024

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

  • The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
    Mon, Dec. 18, 2023

Why Is Aadi Bioscience (AADI) Stock Down 56% Today?

  • Aadi Bioscience (NASDAQ: AADI ) stock is falling on Friday following the release of interim clinical trial data from its PRECISION1 study. This clinical trial covers the use of nab-sirolimus as a treatment for patients with TSC1 or TSC2 inactivating alterations.
    Fri, Dec. 15, 2023

Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript

  • Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President, Investor Relations and Corporate Communications Scott Giacobello - CFO Dave Lennon - President and CEO Loretta Itri - Chief Medical Officer Conference Call Participants Boris Peaker - Cowen Joe Catanzaro - Piper Sandler Roger Song - Jefferies Ahu Demir - Ladenburg Thalmann Operator Good day, and thank you for standing by. Welcome to the Aadi Bioscience Third Quarter 2023 Earnings Conference Call.
    Wed, Nov. 08, 2023

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates

  • Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.73 per share a year ago.
    Wed, Aug. 09, 2023
SEC Filings
SEC Filings

Aadi Bioscience, Inc. (AADI) - ARS

  • SEC Filings
  • 04/26/2024

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 04/26/2024

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/03/2024

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/04/2024

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 02/12/2024

Aadi Bioscience, Inc. (AADI) - S-3

  • SEC Filings
  • 02/12/2024

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 02/02/2024

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 01/02/2024

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/07/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/05/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 11/02/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 10/03/2023

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 10/03/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 09/06/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 08/03/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 07/06/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/20/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/06/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/05/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 05/05/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 05/03/2023

Aadi Bioscience, Inc. (AADI) - ARS

  • SEC Filings
  • 04/28/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/06/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/05/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/04/2023

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 03/29/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/29/2023

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 03/29/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/02/2023

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 01/04/2023

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 11/07/2022

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 11/04/2022

Aadi Bioscience, Inc. (AADI) - UPLOAD

  • SEC Filings
  • 11/01/2022

Aadi Bioscience, Inc. (AADI) - S-3

  • SEC Filings
  • 10/26/2022

Aadi Bioscience, Inc. (AADI) - D

  • SEC Filings
  • 10/11/2022

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 10/04/2022

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 09/27/2022

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 09/26/2022

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/17/2022

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/05/2022

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/22/2022

Aadi Bioscience, Inc. (AADI) - 424B5

  • SEC Filings
  • 03/21/2022

Aadi Bioscience, Inc. (AADI) - 424B5

  • SEC Filings
  • 03/18/2022

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 03/17/2022

Aadi Bioscience, Inc. (AADI) - 424B5

  • SEC Filings
  • 03/17/2022

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 02/14/2022

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 11/29/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 10/25/2021

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 10/25/2021

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 10/04/2021

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 10/04/2021

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 10/04/2021

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 10/01/2021

Aadi Bioscience, Inc. (AADI) - UPLOAD

  • SEC Filings
  • 09/29/2021

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 09/24/2021

Aadi Bioscience, Inc. (AADI) - S-3

  • SEC Filings
  • 09/24/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 09/22/2021

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 09/22/2021

Aadi Bioscience, Inc. (AADI) - D

  • SEC Filings
  • 09/10/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 09/10/2021

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 09/10/2021

Aadi Bioscience, Inc. (AADI) - SC 13D

  • SEC Filings
  • 09/08/2021

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 09/07/2021

Aadi Bioscience, Inc. (AADI) - SC 13D

  • SEC Filings
  • 09/07/2021

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 09/02/2021

Aadi Bioscience, Inc. (AADI) - 4/A

  • SEC Filings
  • 08/31/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 08/31/2021

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 08/31/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 08/30/2021

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 08/30/2021

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 08/23/2021

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 07/12/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 07/02/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/22/2021

Aadi Bioscience, Inc. (AADI) - SC 13D

  • SEC Filings
  • 06/04/2021

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 05/26/2021

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 04/16/2021

Aadi Bioscience, Inc. (AADI) - UPLOAD

  • SEC Filings
  • 04/12/2021

Aadi Bioscience, Inc. (AADI) - S-3

  • SEC Filings
  • 04/08/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/02/2021

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 02/10/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 02/03/2021

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 01/11/2021

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/10/2020

Aadi Bioscience, Inc. (AADI) - 424B5

  • SEC Filings
  • 09/25/2020

Aadi Bioscience, Inc. (AADI) - 424B5

  • SEC Filings
  • 08/05/2020

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/26/2020

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/18/2020

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 03/16/2020

Aadi Bioscience, Inc. (AADI) - SC 13G

  • SEC Filings
  • 03/09/2020

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 11/06/2019

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 10/24/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 07/10/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 07/08/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/19/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 05/16/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/29/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/24/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/15/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/10/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/05/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/02/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/28/2019

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 03/07/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 02/20/2019

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 02/13/2019

Aadi Bioscience, Inc. (AADI) - 5

  • SEC Filings
  • 02/13/2019

Aadi Bioscience, Inc. (AADI) - UPLOAD

  • SEC Filings
  • 02/11/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 01/10/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 01/07/2019

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 01/02/2019

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 12/28/2018

Aadi Bioscience, Inc. (AADI) - S-3

  • SEC Filings
  • 12/28/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/27/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/20/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/14/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/11/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/06/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 11/30/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 11/16/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 11/14/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 09/26/2018

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 09/19/2018

Aadi Bioscience, Inc. (AADI) - UPLOAD

  • SEC Filings
  • 09/11/2018

Aadi Bioscience, Inc. (AADI) - POS AM

  • SEC Filings
  • 08/31/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 08/22/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 07/02/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/29/2018

Aadi Bioscience, Inc. (AADI) - 424B5

  • SEC Filings
  • 06/26/2018

Aadi Bioscience, Inc. (AADI) - CERT

  • SEC Filings
  • 06/25/2018

Aadi Bioscience, Inc. (AADI) - 8-A12B

  • SEC Filings
  • 06/25/2018

Aadi Bioscience, Inc. (AADI) - 424B5

  • SEC Filings
  • 06/25/2018

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 06/25/2018

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 06/22/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 06/22/2018

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 06/22/2018

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 06/11/2018

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 05/25/2018

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 05/21/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 04/25/2018

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 04/12/2018

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 04/06/2018

Aadi Bioscience, Inc. (AADI) - S-3/A

  • SEC Filings
  • 04/06/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/23/2018

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/21/2018

Aadi Bioscience, Inc. (AADI) - S-3

  • SEC Filings
  • 02/21/2018

Aadi Bioscience, Inc. (AADI) - 5

  • SEC Filings
  • 02/14/2018

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 12/18/2017

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 12/18/2017

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 12/06/2017

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 11/16/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 11/14/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 11/13/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 10/10/2017

Aadi Bioscience, Inc. (AADI) - S-8

  • SEC Filings
  • 08/18/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 08/15/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 08/08/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 07/31/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 06/29/2017

Aadi Bioscience, Inc. (AADI) - EFFECT

  • SEC Filings
  • 06/26/2017

Aadi Bioscience, Inc. (AADI) - 424B3

  • SEC Filings
  • 06/26/2017

Aadi Bioscience, Inc. (AADI) - S-1/A

  • SEC Filings
  • 06/09/2017

Aadi Bioscience, Inc. (AADI) - UPLOAD

  • SEC Filings
  • 06/08/2017

Aadi Bioscience, Inc. (AADI) - S-1/A

  • SEC Filings
  • 05/22/2017

Aadi Bioscience, Inc. (AADI) - UPLOAD

  • SEC Filings
  • 05/15/2017

Aadi Bioscience, Inc. (AADI) - S-1

  • SEC Filings
  • 04/14/2017

Aadi Bioscience, Inc. (AADI) - D

  • SEC Filings
  • 03/30/2017

Aadi Bioscience, Inc. (AADI) - SC 13D

  • SEC Filings
  • 03/28/2017

Aadi Bioscience, Inc. (AADI) - SC 13D

  • SEC Filings
  • 03/27/2017

Aadi Bioscience, Inc. (AADI) - 4

  • SEC Filings
  • 03/17/2017

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 03/17/2017

Aadi Bioscience, Inc. (AADI) - 10QSB

  • SEC Filings
  • 08/11/2008

Aadi Bioscience, Inc. (AADI) - 10QSB

  • SEC Filings
  • 05/15/2008

Aadi Bioscience, Inc. (AADI) - SC 13D

  • SEC Filings
  • 04/04/2008

Aadi Bioscience, Inc. (AADI) - 3

  • SEC Filings
  • 04/04/2008
Press Releases
StockPrice Release
More Headlines
News

Aadi Bioscience: High Risk/High Reward

  • Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is approved for one rare indication and is being evaluated for additional tumor types. An investment analysis follows in the paragraphs below.
  • 06/29/2023

Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

  • LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.
  • 04/14/2023

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023

  • LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL.  The details of the poster presentations are below: Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I) " Date and Time: Monday, April 17, 2023, 9:00 AM - 12:30 PM Session Title: Phase II and Phase III Clinical Trials in Progress  Presentation Number: CT057 Title: "Synergistic anti-tumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts" Date and Time: Tuesday, April 18, 2023, 1:30 - 5:00 PM Session Category: Clinical Research Excluding Trials Session Title: Poster Combination Therapies for Cancer Presentation Number: 5484 Title: " Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations " Date and Time: Wednesday, April 19, 2023, 9:00 AM - 12:30 PM Session Category: Clinical Research Excluding Trials Session Title: Late-Breaking Research: Clinical Research 3 Presentation Number: LB288 Full session and meeting details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR.
  • 04/06/2023

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates

  • Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 03/28/2023

Aadi Bioscience: Commercial Stage With Large Market In Label Expansion

  • AADI is a commercial stage company with a potential label expansion ahead. It is adequately funded, run by expert management, and has a major catalyst next year.
  • 03/06/2023

Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?

  • Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  • 01/06/2023

Aadi Bioscience, Inc. (AADI) Q3 2022 Earnings Call Transcript

  • Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Marcy Graham - Senior Vice President of Investor Relations & Corporate Communications Neil Desai - President & Chief Executive Officer Brendan Delaney - Chief Operating Officer Loretta Itri - Chief Medical Officer Scott Giacobello - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - Cowen Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience, Inc. Third Quarter Earnings Conference Call.
  • 11/09/2022

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

  • Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals. Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide therapeutic index and greater target suppression.
  • 09/21/2022

Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q2 2022 Results - Earnings Call Transcript

  • Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Neil Desai - President and CEO Brendan Delaney - COO Loretta Itri - Chief Medical Officer Scott Giacobello - CFO Conference Call Participants Boris Peaker - Cowen Jiale Song - Jefferies Robert Burns - H.C. Wainwright Operator Good day and thank you for standing by.
  • 08/10/2022

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference

  • LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi's executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL.
  • 05/18/2022

Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q1 2022 Results - Earnings Call Transcript

  • Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Quan - VP, Business Development & Corporate Strategy Neil Desai - Founder, President, CEO, Secretary & Director Brendan Delaney - COO Loretta Itri - Chief Medical Officer Scott Giacobello - CFO & Treasurer Conference Call Participants Boris Peaker - Cowen and Company Ahu Demir - Ladenburg Thalmann & Co. Joseph Catanzaro - Piper Sandler & Co. Jiale Song - Jefferies Operator Greetings, and welcome to the Aadi Bioscience, Inc. First Quarter 2021 Earnings Conference Call. [Operator Instructions].
  • 05/12/2022

Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

  • Company to hold conference call on May 12th at 8:30 am EDT Company to hold conference call on May 12th at 8:30 am EDT
  • 04/28/2022

Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

  • LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. The presentation will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.
  • 01/04/2022

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

  • Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa. Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring access to thousands of new patients.
  • 11/25/2021

Aadi Bioscience (AADI) Stock: Why The Price Surged Today

  • The stock price of Aadi Bioscience Inc (NASDAQ: AADI) increased by over 25% pre-market today. This is why it happened.
  • 11/23/2021

Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer

  • The FDA has approved Aadi Bioscience Inc's (NASDAQ: AADI) Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa). The approval marks the first and only therapy for adult patients for locally advanced unresectable or metastatic malignant PEComa.
  • 11/23/2021

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Misses Revenue Estimates

  • Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -132.20% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 11/10/2021

Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer

  • LOS ANGELES, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Brendan Delaney to the role of Chief Operating Officer (COO). Brendan has had an established career in oncology-focused commercial leadership roles, launching multiple groundbreaking new products and building effective and cohesive commercial teams. Most recently Brendan was Chief Commercial Officer at Constellation Pharmaceuticals, which was acquired by MorphoSys AG for $1.4 billion prior to a commercial launch of pelabresib a first-in-class BETi inhibitor with blockbuster potential across multiple hematology indications. Prior to this, as Chief Commercial Officer at Immunomedics, Inc. Brendan led the launch of TRODELVY®, the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer which was acquired by Gilead Sciences, Inc. for $21 billion.
  • 09/20/2021
Unlock
AADI Ratings Summary
AADI Quant Ranking